MedKoo Cat#: 555457 | Name: Diprovocim
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Diprovocim is a potent Toll-like receptor TLR1/TLR2 agonist that induces dose-dependent TNF production with EC50 of 110 pM. Diprovocim has shown significant adjuvant activity in anticancer vaccination against murine melanoma. Diprovocim exhibited an EC50 of 110 pM in human THP-1 cells and 1.3 nM in primary mouse peritoneal macrophages. In mice, Diprovocim-adjuvanted ovalbumin immunization promoted antigen-specific humoral and CTL responses and synergized with anti-PD-L1 treatment to inhibit tumor growth, generating long-term antitumor memory, curing or prolonging survival of mice engrafted with the murine melanoma B16-OVA. Diprovocim induced greater frequencies of tumor-infiltrating leukocytes than alum, of which CD8 T cells were necessary for the antitumor effect of immunization plus anti-PD-L1 treatment.

Chemical Structure

Diprovocim
Diprovocim
CAS#2170867-89-5

Theoretical Analysis

MedKoo Cat#: 555457

Name: Diprovocim

CAS#: 2170867-89-5

Chemical Formula: C56H56N6O6

Exact Mass: 908.4261

Molecular Weight: 909.10

Elemental Analysis: C, 73.99; H, 6.21; N, 9.24; O, 10.56

Price and Availability

Size Price Availability Quantity
5mg USD 385.00 2 Weeks
10mg USD 685.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
Diprovocim; Diprovocim-1;
IUPAC/Chemical Name
(3S,3'S,4S,4'S)-1,1'-terephthaloylbis(N3,N4-bis((1S,2R)-2-phenylcyclopropyl)pyrrolidine-3,4-dicarboxamide)
InChi Key
ABZBNXFGYUSVCJ-UYMKNZQYSA-N
InChi Code
InChI=1S/C56H56N6O6/c63-51(57-47-25-39(47)33-13-5-1-6-14-33)43-29-61(30-44(43)52(64)58-48-26-40(48)34-15-7-2-8-16-34)55(67)37-21-23-38(24-22-37)56(68)62-31-45(53(65)59-49-27-41(49)35-17-9-3-10-18-35)46(32-62)54(66)60-50-28-42(50)36-19-11-4-12-20-36/h1-24,39-50H,25-32H2,(H,57,63)(H,58,64)(H,59,65)(H,60,66)/t39-,40-,41-,42-,43-,44-,45-,46-,47+,48+,49+,50+/m1/s1
SMILES Code
O=C(N1C[C@@H](C(N[C@@H]2[C@@H](C3=CC=CC=C3)C2)=O)[C@H](C(N[C@@H]4[C@@H](C5=CC=CC=C5)C4)=O)C1)C6=CC=C(C(N7C[C@@H](C(N[C@@H]8[C@@H](C9=CC=CC=C9)C8)=O)[C@H](C(N[C@@H]%10[C@@H](C%11=CC=CC=C%11)C%10)=O)C7)=O)C=C6
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Biological target:
Diprovocim is a potent Toll-like receptor TLR1/TLR2 agonist that induces dose-dependent TNF production with EC50 of 110 pM.
In vitro activity:
Diprovocim induced formation of TLR2 (but not TLR1) homodimers (Figure 1B). In the presence of both TLR2 and TLR1 ectodomains, Diprovocim induced both TLR2/TLR2 homodimers and TLR2/TLR1 heterodimers detectable by immunoblot. Reference: J Med Chem. 2019 Mar 28;62(6):2938-2949. https://pubmed.ncbi.nlm.nih.gov/30829478/
In vivo activity:
In mice, Diprovocim-adjuvanted ovalbumin immunization promoted antigen-specific humoral and CTL responses and synergized with anti-PD-L1 treatment to inhibit tumor growth, generating long-term antitumor memory, curing or prolonging survival of mice engrafted with the murine melanoma B16-OVA. Reference: Proc Natl Acad Sci U S A. 2018 Sep 11;115(37):E8698-E8706. https://pubmed.ncbi.nlm.nih.gov/30150374/

Preparing Stock Solutions

The following data is based on the product molecular weight 909.10 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Su L, Wang Y, Wang J, Mifune Y, Morin MD, Jones BT, Moresco EMY, Boger DL, Beutler B, Zhang H. Structural Basis of TLR2/TLR1 Activation by the Synthetic Agonist Diprovocim. J Med Chem. 2019 Mar 28;62(6):2938-2949. doi: 10.1021/acs.jmedchem.8b01583. Epub 2019 Mar 13. PMID: 30829478; PMCID: PMC6537610. 2. Morin MD, Wang Y, Jones BT, Mifune Y, Su L, Shi H, Moresco EMY, Zhang H, Beutler B, Boger DL. Diprovocims: A New and Exceptionally Potent Class of Toll-like Receptor Agonists. J Am Chem Soc. 2018 Oct 31;140(43):14440-14454. doi: 10.1021/jacs.8b09223. Epub 2018 Oct 16. PMID: 30272974; PMCID: PMC6209530. 3. Yang MH, Russell JL, Mifune Y, Wang Y, Shi H, Moresco EMY, Siegwart DJ, Beutler B, Boger DL. Next-Generation Diprovocims with Potent Human and Murine TLR1/TLR2 Agonist Activity That Activate the Innate and Adaptive Immune Response. J Med Chem. 2022 Jul 14;65(13):9230-9252. doi: 10.1021/acs.jmedchem.2c00419. Epub 2022 Jun 29. PMID: 35767437; PMCID: PMC9283309. 4. Wang Y, Su L, Morin MD, Jones BT, Mifune Y, Shi H, Wang KW, Zhan X, Liu A, Wang J, Li X, Tang M, Ludwig S, Hildebrand S, Zhou K, Siegwart DJ, Moresco EMY, Zhang H, Boger DL, Beutler B. Adjuvant effect of the novel TLR1/TLR2 agonist Diprovocim synergizes with anti-PD-L1 to eliminate melanoma in mice. Proc Natl Acad Sci U S A. 2018 Sep 11;115(37):E8698-E8706. doi: 10.1073/pnas.1809232115. Epub 2018 Aug 27. PMID: 30150374; PMCID: PMC6140543.
In vitro protocol:
1. Su L, Wang Y, Wang J, Mifune Y, Morin MD, Jones BT, Moresco EMY, Boger DL, Beutler B, Zhang H. Structural Basis of TLR2/TLR1 Activation by the Synthetic Agonist Diprovocim. J Med Chem. 2019 Mar 28;62(6):2938-2949. doi: 10.1021/acs.jmedchem.8b01583. Epub 2019 Mar 13. PMID: 30829478; PMCID: PMC6537610. 2. Morin MD, Wang Y, Jones BT, Mifune Y, Su L, Shi H, Moresco EMY, Zhang H, Beutler B, Boger DL. Diprovocims: A New and Exceptionally Potent Class of Toll-like Receptor Agonists. J Am Chem Soc. 2018 Oct 31;140(43):14440-14454. doi: 10.1021/jacs.8b09223. Epub 2018 Oct 16. PMID: 30272974; PMCID: PMC6209530.
In vivo protocol:
1. Yang MH, Russell JL, Mifune Y, Wang Y, Shi H, Moresco EMY, Siegwart DJ, Beutler B, Boger DL. Next-Generation Diprovocims with Potent Human and Murine TLR1/TLR2 Agonist Activity That Activate the Innate and Adaptive Immune Response. J Med Chem. 2022 Jul 14;65(13):9230-9252. doi: 10.1021/acs.jmedchem.2c00419. Epub 2022 Jun 29. PMID: 35767437; PMCID: PMC9283309. 2. Wang Y, Su L, Morin MD, Jones BT, Mifune Y, Shi H, Wang KW, Zhan X, Liu A, Wang J, Li X, Tang M, Ludwig S, Hildebrand S, Zhou K, Siegwart DJ, Moresco EMY, Zhang H, Boger DL, Beutler B. Adjuvant effect of the novel TLR1/TLR2 agonist Diprovocim synergizes with anti-PD-L1 to eliminate melanoma in mice. Proc Natl Acad Sci U S A. 2018 Sep 11;115(37):E8698-E8706. doi: 10.1073/pnas.1809232115. Epub 2018 Aug 27. PMID: 30150374; PMCID: PMC6140543.
1: Su L, Wang Y, Wang J, Mifune Y, Morin MD, Jones BT, Moresco EMY, Boger DL, Beutler B, Zhang H. Structural Basis of TLR2/TLR1 Activation by the Synthetic Agonist Diprovocim. J Med Chem. 2019 Mar 28;62(6):2938-2949. doi: 10.1021/acs.jmedchem.8b01583. Epub 2019 Mar 13. PMID: 30829478; PMCID: PMC6537610. 2: Wang X, Wang Y, Zhu Y, Lei X, Zhang M, Li Y. Identification and immunological evaluation of novel TLR2 agonists through structural optimization of Diprovocim. Eur J Med Chem. 2022 Dec 5;243:114771. doi: 10.1016/j.ejmech.2022.114771. Epub 2022 Sep 15. PMID: 36174413. 3: Wang Y, Su L, Morin MD, Jones BT, Mifune Y, Shi H, Wang KW, Zhan X, Liu A, Wang J, Li X, Tang M, Ludwig S, Hildebrand S, Zhou K, Siegwart DJ, Moresco EMY, Zhang H, Boger DL, Beutler B. Adjuvant effect of the novel TLR1/TLR2 agonist Diprovocim synergizes with anti-PD-L1 to eliminate melanoma in mice. Proc Natl Acad Sci U S A. 2018 Sep 11;115(37):E8698-E8706. doi: 10.1073/pnas.1809232115. Epub 2018 Aug 27. PMID: 30150374; PMCID: PMC6140543. 4: Morin MD, Wang Y, Jones BT, Mifune Y, Su L, Shi H, Moresco EMY, Zhang H, Beutler B, Boger DL. Diprovocims: A New and Exceptionally Potent Class of Toll- like Receptor Agonists. J Am Chem Soc. 2018 Oct 31;140(43):14440-14454. doi: 10.1021/jacs.8b09223. Epub 2018 Oct 16. PMID: 30272974; PMCID: PMC6209530. 5: Chen H, Li Y, Li L, Yang Z, Wen Z, Liu L, Liu H, Chen Y. Carrier-free subunit nanovaccine amplifies immune responses against tumors and viral infections. Acta Biomater. 2023 Mar 1;158:525-534. doi: 10.1016/j.actbio.2022.12.042. Epub 2022 Dec 23. PMID: 36572250. 6: Yang MH, Russell JL, Mifune Y, Wang Y, Shi H, Moresco EMY, Siegwart DJ, Beutler B, Boger DL. Next-Generation Diprovocims with Potent Human and Murine TLR1/TLR2 Agonist Activity That Activate the Innate and Adaptive Immune Response. J Med Chem. 2022 Jul 14;65(13):9230-9252. doi: 10.1021/acs.jmedchem.2c00419. Epub 2022 Jun 29. PMID: 35767437; PMCID: PMC9283309. 7: Peng R, Lin H, Zhu H, Zhang Y, Bao T, Li W, Deng J. Involvement of IGF1 in endoplasmic reticulum stress contributes to cataract formation through regulating Nrf2/NF-κB signaling. Funct Integr Genomics. 2023 Jul 3;23(3):220. doi: 10.1007/s10142-023-01152-7. PMID: 37394478.